LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Puma Biotechnology Inc

Închisă

SectorSănătate

3.34 2.77

Rezumat

Modificarea prețului

24h

Curent

Minim

3.25

Maxim

3.51

Indicatori cheie

By Trading Economics

Venit

-16M

3M

Vânzări

-13M

46M

P/E

Medie Sector

4.903

56.602

EPS

0.1

Marjă de profit

6.464

Angajați

172

EBITDA

-14M

4M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+49.31% upside

Dividende

By Dow Jones

Următoarele câștiguri

31 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-8.4M

151M

Deschiderea anterioară

0.57

Închiderea anterioară

3.34

Sentimentul știrilor

By Acuity

60%

40%

325 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Puma Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 mai 2025, 22:52 UTC

Câștiguri
Principalele dinamici ale pieței

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 mai 2025, 20:37 UTC

Top știri
Câștiguri

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 mai 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 mai 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 mai 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 mai 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 mai 2025, 23:14 UTC

Top știri

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 mai 2025, 22:46 UTC

Top știri
Achiziții, Fuziuni, Preluări

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mai 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 mai 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 mai 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mai 2025, 21:58 UTC

Câștiguri

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 mai 2025, 21:24 UTC

Câștiguri

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 mai 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 mai 2025, 20:54 UTC

Market Talk
Câștiguri

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 mai 2025, 20:54 UTC

Câștiguri

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 mai 2025, 20:51 UTC

Câștiguri

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 mai 2025, 20:50 UTC

Achiziții, Fuziuni, Preluări

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 mai 2025, 20:50 UTC

Câștiguri

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 mai 2025, 20:26 UTC

Top știri

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 mai 2025, 20:25 UTC

Câștiguri

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Comparație

Modificare preț

Puma Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

49.31% sus

Prognoză pe 12 luni

Medie 4.33 USD  49.31%

Maxim 7 USD

Minim 2 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPuma Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

3 ratings

1

Cumpărare

1

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

3.07 / 3.075Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

325 / 382 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.